Oppenheimer raised the firm’s price target on Nektar (NKTR) to $98 from $90 and keeps an Outperform rating on the shares following quarterly results. The firm notes Q2 marks an important milestone for Nektar, as the company reported positive topline results from the Phase 2b REZOLVE-AD study of rezpeg in atopic dermatitis. Oppenheimer anticipates additional updates in the coming months, including data presentation in the second half of the year at a medical conference; alopecia areata topline results in December; and maintenance data from REZOLVE-AD in Q1 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance
- Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments
- Nektar Therapeutics Reports Q2 2025 Financial Results
- Nektar reports Q2 adjusted EPS ($2.78), consensus ($3.12)
- NKTR Upcoming Earnings Report: What to Expect?